| scholarly article | Q13442814 |
| P50 | author | Daniel Gonzalez | Q86888058 |
| Michael Cohen-Wolkowiez | Q93049830 | ||
| P2093 | author name string | Charles Peloquin | |
| DAPPER Study Group | |||
| David Jacobus | |||
| Jeffrey T Guptill | |||
| Kathy Aleš | |||
| Laura Jacobus | |||
| Nilay Thakkar | |||
| P2860 | cites work | A web server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype | Q24655489 |
| 3,4-diaminopyridine. A potent new potassium channel blocker | Q28271710 | ||
| PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. | Q33219671 | ||
| Novel drug of choice in Eaton-Lambert syndrome | Q33618996 | ||
| Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome | Q34060833 | ||
| Identifying a cut-off point for normal mobility: a comparison of the timed 'up and go' test in community-dwelling and institutionalised elderly women | Q34193620 | ||
| Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine | Q34206472 | ||
| Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. | Q34233555 | ||
| Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome | Q34542963 | ||
| Prognostic validity of the Timed Up-and-Go test, a modified Get-Up-and-Go test, staff's global judgement and fall history in evaluating fall risk in residential care facilities | Q34783225 | ||
| Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate | Q35049590 | ||
| Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria | Q35363704 | ||
| Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes | Q35774965 | ||
| A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. | Q35949142 | ||
| Diagnosing model diagnostics | Q36850144 | ||
| Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. | Q38428553 | ||
| A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome | Q39529443 | ||
| Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS. | Q40350903 | ||
| 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. | Q43282674 | ||
| Minimal detectable change of the timed "up & go" test and the dynamic gait index in people with Parkinson disease. | Q44447857 | ||
| 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome | Q44449823 | ||
| Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. | Q46055747 | ||
| Effect of 3,4-diaminopyridine at the murine neuromuscular junction | Q46441845 | ||
| Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children | Q47355479 | ||
| 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). | Q47826055 | ||
| Interspecies scaling: predicting volumes, mean residence time and elimination half-life. Some suggestions. | Q52240880 | ||
| The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. | Q59394075 | ||
| Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse | Q71147638 | ||
| Potency of 3,4-Diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes | Q72418552 | ||
| The Timed Get-up-and-Go test revisited: measurement of the component tasks | Q73881064 | ||
| Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors | Q74420444 | ||
| Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM | Q77296898 | ||
| Age- and gender-related test performance in community-dwelling elderly people: Six-Minute Walk Test, Berg Balance Scale, Timed Up & Go Test, and gait speeds | Q77663953 | ||
| P4510 | describes a project that uses | RStudio | Q4798119 |
| ggplot2 | Q326489 | ||
| P433 | issue | 9 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 625-634 | |
| P577 | publication date | 2017-06-17 | |
| P1433 | published in | CPT: pharmacometrics & systems pharmacology | Q27724610 |
| P1476 | title | Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia | |
| P478 | volume | 6 |
| Q49561997 | 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia |
| Q57471361 | Reported direct aminopyridine effects on voltage-gated calcium channels is a high-dose pharmacological off-target effect of no clinical relevance |
| Q93038062 | Symptomatic treatment of botulism with a clinically approved small molecule |
Search more.